Bermuda
|
001-37418
|
98-1333697
|
||||||||||||
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
Suite 1, 3rd Floor
11-12 St. James’s Square
London SW1Y 4LB, United Kingdom
(Address of principal executive offices) (Zip Code)
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|||||||
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|||||||
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|||||||
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each Class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
||||||||||||
Common Shares, par value $0.00001 per share
|
AXGT
|
The Nasdaq Stock Market LLC
|
Name | Votes For | Votes Against | Abstain | Broker Non-Votes | ||||||||||||||||||||||
Frank Torti, M.D. | 17,715,500 | 2,472,995 | 22,663 | 16,803,101 | ||||||||||||||||||||||
Atul Pande, M.D. | 19,857,330 | 329,778 | 24,050 | 16,803,101 | ||||||||||||||||||||||
Pavan Cheruvu, M.D. | 17,710,786 | 2,475,333 | 25,039 | 16,803,101 | ||||||||||||||||||||||
Berndt Modig | 19,906,804 | 276,494 | 27,860 | 16,803,101 | ||||||||||||||||||||||
Senthil Sundaram | 19,847,132 | 331,586 | 32,440 | 16,803,101 | ||||||||||||||||||||||
Eric Venker, M.D., Pharm.D. | 17,741,465 | 2,441,958 | 27,735 | 16,803,101 |
Votes For | Votes Against | Abstain | ||||||||||||
36,771,288 | 163,819 | 79,152 |
AXOVANT GENE THERAPIES LTD. | |||||||||||
Dated: September 28, 2020 | |||||||||||
By: | /s/ David Nassif | ||||||||||
Name: | David Nassif | ||||||||||
Title: | Principal Financial Officer and Principal Accounting Officer, General Counsel |